Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Graham To Present Overview At COX-2 Advisory Committee Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Office of Drug Safety Director for Science & Medicine David Graham is scheduled to present an "epidemiological overview" on Feb. 16, day one of the three-day meeting. Senate Finance Committee Chairman Charles Grassley is concerned that FDA has forbidden Graham from discussing certain data.
Advertisement

Related Content

FDA To Act On COX-2 Committee Input Within "Next Few Weeks"
Celebrex Has No Apparent MI Signal At 200 Mg Or Less, FDAer Graham Says
Celebrex Has No Apparent MI Signal At 200 Mg Or Less, FDAer Graham Says
FDA To Act On COX-2 Committee Input Within "Next Few Weeks"
Sen. Grassley Targets FDA's Handling Of Adderall XR Adverse Events
Sen. Grassley Targets FDA's Handling Of Adderall XR Adverse Events

Topics

Advertisement
UsernamePublicRestriction

Register

PS061550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel